

IN THE CLAIMS:

Please amend claims 18, 44, 72, 81, 82, 139, 179 and 192 to read as follows:

Q32 18. (amended) The method of claim 1 or 2, wherein at least one of the antibodies has the amino acid sequence of SYNAGIS®, AFFF, P12f2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4, or A8c7.

Q33 44. (amended) The method of claim 19 or 20, wherein at least one of the antibodies has the amino acid sequence of SYNAGIS®, AFFF, P12f2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4, or A8c7.

Q34 72. (amended) The method of claim 45 or 46, wherein at least one of the antibodies has an amino acid sequence of SYNAGIS®, AFFF, P12f2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4, or A8c7.

Q35 81. (amended) The sustained release formulation of claim 73, wherein at least one of said antibodies at least one of the antibodies has an amino acid sequence of SYNAGIS®, AFFF, P12f2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4, or A8c7.

82. (amended) The pharmaceutical composition of claim 74, wherein at least one of said antibodies at least one of the antibodies has an amino acid sequence of SYNAGIS®, AFFF, P12f2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4, or A8c7.

Q36 139. (amended) The method of claim 123 or 124, wherein at least one of the antibodies has an amino acid sequence of SYNAGIS®, AFFF, P12f2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4, or A8c7.

Q37 179. (amended) The method of claim 156 or 157, wherein at least one of said antibodies comprises a VH CDR1 having the amino acid sequence of SEQ ID NO:1, SEQ ID NO:10 or SEQ ID NO:17, a VH CDR2 having the amino acid sequence of SEQ ID NO:2, SEQ ID NO:18, SEQ ID NO:24, SEQ ID NO:37, SEQ ID NO:41 or SEQ ID NO:45, a VH CDR3 having the amino acid sequence of SEQ ID NO:3, SEQ ID NO:11, SEQ ID NO:19, SEQ ID NO:26 or SEQ ID NO:29, a VL CDR1 having the amino acid sequence of